Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET
Company Participants
Courtney Solberg - Manager of Corporate Communications & Investor Relations
Nancy Simonian - Chief Executive Officer
David Roth - Chief Medical Officer
Jason Haas - Chief Financial Officer
Conference Call Participants
Phil Nadeau - Cowen & Company
Jason Butler - JMP Securities
Mark Breidenbach - Oppenheimer
Operator
Good morning, and welcome to Syros Pharmaceuticals Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode. This call is being webcast live on the Investor Relations and Media section of Syros' website at www.syros.com. Please be advised that today's call is being recorded.
At this time, I would like to turn the call over to Courtney Solberg, Manager of Corporate Communications and Investor Relations at Syros.
Courtney Solberg
Thank you. This morning, we issued a press release announcing our second quarter 2022 financial results and a broader business update. The release is available in the Investors and Media section of Syros' website at www.syros.com. We'll begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer, Dr. David Roth, our Chief Medical Officer, and Jason Haas, our Chief Financial Officer. We will then open the call for questions. Kristin Stephens, our Chief Development Officer; Dr. Eric Olson our Chief Scientific Officer; and Conley Chee, our Chief Commercial Officer are also on the call and will be available for Q&A.
Before we begin, I would like to remind everyone that statements we make on this conference call will include forward-looking statements including statements related to our planned strategic merger with TYME Technologies and concurrent private placement. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors including those set forth in the Risk Factors section of our annual report on Form 10-K and our quarterly report on Form 10-Q that we filed this morning and any other filings that we may make with the SEC in the future.
In particular, to the extent to which the COVID-19 pandemic continues to impact our operations and those of the third parties on which we rely will depend on future developments, which are highly uncertain and cannot be predicted with confidence. Any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.